ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
16 hedge funds and large institutions have $10.1M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 8 closing their positions.
53% more capital invested
Capital invested by funds: $6.59M → $10.1M (+$3.47M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
33% less funds holding
Funds holding: 24 → 16 (-8)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$7.68M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$312K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5K |
| 4 |
WW
Waterfront Wealth
Overland Park,
Kansas
|
+$3.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$480K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$126K |
| 3 |
Renaissance Technologies
New York
|
-$38.9K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$33.2K |
| 5 |
VF
Virtu Financial
New York
|
-$32K |
ASLN Hedge Fund Activity: Q1 2023 in Review
16 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q1 2023, worth a combined $10.1M — up 53% from $6.59M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ASLN and 0 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Vivo Capital, adding an estimated $7.68M. The largest seller was Millennium Management, cutting an estimated $480K.
- 16 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q1 2023, down from 24 in Q4 2022.
- Funds reported $10.1M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q1 2023, up 53% quarter-over-quarter.
- 0 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q1 2023 and 8 closed out, a net change of -8 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q1 2023 was Vivo Capital, an estimated $7.68M added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q1 2023 was Millennium Management, an estimated $480K sold.
Based on aggregated 13F filings for Q1 2023.